A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Latest Information Update: 27 Jul 2023
At a glance
- Drugs Bizalimogene ralaplasmid (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Registrational; Therapeutic Use
- Acronyms REVEAL 1
- Sponsors Inovio Pharmaceuticals
- 14 Dec 2021 52-week safety follow-up results published in an Inovio Pharmaceuticals media release.
- 14 Dec 2021 According to an Inovio Pharmaceuticals media release, the company has completed the 52-week safety follow-up of participants.
- 14 Dec 2021 According to an Inovio Pharmaceuticals media release, results are expected in 2H 2022.